[Retracted] Synthesis and Evaluation of Finasteride-Loaded HPMC-Based Nanogels for Transdermal Delivery: A Versatile Nanoscopic Platform

Table 4

Clinical observations of toxicity studies.

Parameter observed	Time for observation	Group I (control)			Group III (treated with HPMC nanogels) 500 mg/kg of body weight
Body weight (kg)	Pretreatment
	24 h
	48 h
	72 h
	240 h
Food intake (g/day)	Pretreatment
	24 h
	48 h
	72 h
	240 h
Water intake (ml/day)	Pretreatment
	24 h
	48 h
	72 h
	240 h
		R1	R2	R3	R1	R2	R3
Signs of illness	Pretreatment	0	0	0	0	0	0
	24 h	0	0	0	0	0	0
	48 h	0	0	0	0	0	1
	72 h	0	0	0	0	1	0
	240 h	0	0	0	0	0	0
Convulsion	Pretreatment	0	0	0	0	0	0
	24 h	0	0	0	0	0	0
	48 h	0	0	0	0	0	0
	72 h	0	0	0	0	0	0
	240 h	0	0	0	0	0	0
Hyperactivity	Pretreatment	0	0	0	0	0	0
	24 h	0	0	0	0	0	1
	48 h	0	0	2	1	0	0
	72 h	0	0	0	0	1	0
	240 h	0	0	0	0	0	1
Pain response	Pretreatment	1	1	1	1	1	1
	24 h	1	1	1	1	1	1
	48 h	1	0	1	0	1	1
	72 h	1	1	1	1	1	0
	240 h	1	1	1	1	1	1
Scale	Sign			0	1	2	3
	Outcome			Absent	Mild	Moderate	Intense